SCHEMBL337002

SCHEMBL337002

CCN(CC)c1ccc(C(=O)NC(c2ccc(C(C)C)cc2)C(O)C(=O)Nc2ccc3nc(N)[nH]c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
F9 P00740 1/20 0.38
F7 P08709 1/20 0.38
NR2E3 Q9Y5X4 1/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
IKBKB O14920 1/20 0.37
CNR2 P34972 1/20 0.37
ESRRG P62508 1/20 0.37
HCRTR1 O43613 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335484 0.93 MAPT (0.43) MAPTSMN1; SMN2F9F7NR2E3
SCHEMBL336353 0.92 MAPT (0.43) MAPTSMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL335848 0.91 MCHR1 (0.42) MAPTSMN1; SMN2F9F7IKBKB
SCHEMBL335303 0.90 MAPT (0.40) MAPTSMN1; SMN2F9F7LMNA
SCHEMBL336687 0.89 MAPT (0.39) MAPTSMN1; SMN2F9F7NR2E3
SCHEMBL335878 0.88 ABL1 (0.43) MAPTSMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL335968 0.88 MAPT (0.41) MAPTSMN1; SMN2F9F7LMNA
SCHEMBL336083 0.88 F9 (0.41) MAPTSMN1; SMN2F9F7LMNA
SCHEMBL335524 0.87 NR2E3 (0.43) MAPTSMN1; SMN2F9F7NR2E3
SCHEMBL335326 0.86 PDE2A (0.44) MAPTSMN1; SMN2HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 MAPT 3998/4885SMN1; SMN2 4382/4885EGFR 2699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.